This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
120
600mg every 12 hours
1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
Clinical efficacy of linezolid when administered intravenously as compared to intravenously administered vancomycin in the empiric treatment of oncology patients with febrile neutropenia with suspected gram-positive infections.
Time frame: 7-28 days
Microbiologic outcome
Time frame: 7-28 days
Pathogen eradication (eradication rates of individual pathogens)
Time frame: 7-28 days
Defervescence (defined as Tmax orally or rectally)
Time frame: 7-28 days
Time to defervescence
Time frame: 7-28 days
Resolution of neutropenia (return of ANC to >500 cells/mm3)
Time frame: 7-28 days
Time to resolution of neutropenia
Time frame: 7-28 days
Mortality rate (survival at 7 days after the end of therapy)
Time frame: 7-28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Springfield, Illinois, United States
Pfizer Investigational Site
Springfield, Illinois, United States
Pfizer Investigational Site
Springfield, Illinois, United States
Pfizer Investigational Site
Springfield, Illinois, United States
Pfizer Investigational Site
The Bronx, New York, United States
Pfizer Investigational Site
The Bronx, New York, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
...and 30 more locations